Oncotarget

Research Papers:

MicroRNA-466 with tumor markers for cervical cancer screening

Li-Li Zhou _, Yong Shen, Jiao-Mei Gong, Ping Sun and Jia-He Sheng

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:70821-70827. https://doi.org/10.18632/oncotarget.19992

Metrics: PDF 1801 views  |   HTML 2407 views  |   ?  


Abstract

Li-Li Zhou1,*, Yong Shen1,*, Jiao-Mei Gong2,*, Ping Sun1 and Jia-He Sheng1

1Department of Clinical Laboratory, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China

2Department of Clinical Laboratory, Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

*These authors have contributed equally to this work

Correspondence to:

Li-Li Zhou, email: [email protected]

Keywords: microRNA-466, cervical cancer, tumor marker, screening, diagnoses

Received: June 20, 2017    Accepted: July 13, 2017    Published: August 07, 2017

ABSTRACT

Cervical cancer is the second most common cancer in women in the world. In this study, we explore tumor markers and microRNA-466 combination for cervical cancer screening. Tumor markers were measured by the methods of electro-chemiluminescent immunoassay and enzyme immunoassay. The microRNA-466 was performed by quantitative real-time polymerase chain reaction. Among normal group, hyperplasia group and cancer group, the CEA expression levels were 2.26 ng/ml, 3.85 ng/ml and 16.08 ng/ml, respectively. While the CA125 expression levels were 13.61 u/ml, 27.32 u/ml and 44.93 u/ml, respectively. The SCCA expression levels were 13.61 ng/ml, 27.32 ng/ml and 44.93 ng/ml, respectively. The expression levels of tumor markers were all gradually increased with the development of cervical lesions. The expression levels of microRNA-466 in cervical cancers (0.62) were greater than that in normal (0.076) and hyperplasia (0.24). The expression of microRNA-466 was correlated with lymphnode metastasis (P=0.000). There is a lower overall survival rate of patient with large tumor or lymphnode metastasis. Thus, the combination of tumor markers and microRNA-466 can be useful for early detection of cervical cancer and indicators for advanced stage and prognosis of the disease.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19992